Management changes at Mylan, Transition Thera, Pfizer and ShangPharma
US generic drug major Mylan (Nasdaq: MYL) has announced the appointment of John Thievon as president of Dey Pharma, its fully integrated specialty pharmaceutical business.
Mr Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership. Most recently, he served as president and chief executive of MiddleBrook Pharmaceuticals. In this capacity, he helped build the company from an 18-person start-up to a 450-person organization before the company's assets were acquired by Victory Pharma.
Pfizer elects CEO Ian Read as chairman of the board
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze